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Background/Aim: Inﬂammatory cytokines is a key point in the development of pathogenesis of SAP. In-
ﬂammatory mediators TNF-a and IL-6 are up-regulated in serum of patients with SAP and become good
discriminators of SAP severity.
Materials and methods: In this study, we investigated the treatment effectiveness of Baicalein on SAP rat
model. Baicalein was intravenously injected immediately after SAP induction in rats. The mortality,
histopathology score, ascites ﬂuid volume, and pro-inﬂammatory cytokine production were evaluated at
12 h after SAP induction.
Results: Baicalein decreased the pancreatic histopathology score, reduced ascites ﬂuid production, pro-
tected against pancreatic injury, and improved survival in rats with SAP. The serum IL-6 and TNF-a
concentrations were also down-regulated by Baicalein.
Conclusion: Baicalein demonstrated a well curative capability on rats with SAP. The mechanism may be
alleviateing pancreatic injury and inhibiting pro-inﬂammatory cytokines expression.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
SAP is a serious necro-inﬂammatory disease with a high
morbidity and mortality rate due to lack of speciﬁc therapy. How-
ever, the pathogenesis of SAP has not yet been clariﬁed [1,2]. More
than a century ago, Chiari et al. observed that prematurely activatedineering Research Center of
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Inc. This is an open access article udigestive enzymes in the pancreas in SAP patients are responsible
for this debilitating disease [3]. Inﬂammatory mediators is vital for
progression of SAP and has been receiving increasing attention in
recent years. SAP is a potentially lethal inﬂammatory condition of
the pancreas that involves both peripancreatic tissue and remote
organs. The inﬂammatory pathways participate in this disease from
early stage to the end. Local inﬂammatory reaction in pancreas
leads to systemic inﬂammatory response syndrome (SIRS) and
multiorgan failure (MOF), which is believed to be the capital cause
of mortality [4,5]. Inﬂammatory components include interleukin
(IL)-6, tumor necrosis factor (TNF)-a, platelet-activating factor, IL-8,
IL-10, monocyte chemotactic protein-1 (MCP-1), and IL-1b are
considered to be required for SAP development [6]. These inﬂam-
matory mediators are produced by many different cell types
include neutrophils, monocytes, pancreatic acinar cells, macro-
phages, and lymphocytes [4e10]. A recent study has shown that
pro-inﬂammatory stimuli such as IL-6 and TNF-a play a central role
in the initiation and progression of SAP [11]. TNF-a is thought to
induce a cascade of other inﬂammatory cytokines and activatender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Criteria for microscopical assessment.
Histological patterns Assessment Score
Edema Mild 1
Moderate 2
Severe 3
Inﬂammatory inﬁltration Mild 1
Moderate 2
Severe 3
Fat necrosis <2/section 3
3e5/section 5
>5/section 7
Parenchymal necrosis Focal (<5%) 3
And/or sublobular (<20%) 5
And/or lobular (>20%) 7
Hemorrhages Mild 3
Moderate 5
Severe 7
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response [12,13]. It has been conﬁrmed that the IL-6 level in serum
is a very good discriminator of SAP, and when accompanied by
multi-organ failure could be used as an early marker of a possible
fatal outcome [9]. TNF-a and IL-6 aggravate SAP and increase
plasma extravasation, inducing leukocyte adherence, resulting in
SIRS and MODS [14]. Preventing the activity of both cytokines can
markedly attenuate the systemic ampliﬁcation of SAP, which is
responsible for the increased mortality associated with SAP.
To enhance therapeutic efﬁcacy, practitioners of traditional
Chinese medicine use formulae to treat patients with SAP based on
clinical experience. The well-known formula to treat SAP is known
as “Qingyi Decoction” therapy and has been advocated for 100
years. A major component of the formulae, Scutellaria baicalensis
Georgi (“Huang-Qin” in Chinese), is used clinically to treat SAP and
exhibits many biological activities, such as antipyretic, antibacte-
rial, and anti-inﬂammatory properties. Baicalein (5,6,7-
trihydroxyﬂavone-7-O-D-glucuronic acid), a ﬂavonoid, with the
molecular formula C15H10O5 and a molecular mass of 270.24, is
isolated from the Chinese traditional medicine herb S. baicalensis
Georgi. It is the principal component with bioactivity of
S. baicalensis and has excellent antioxidant and anti-inﬂammatory
activities [15e18]. Baicalein has been reported to exhibit a prop-
erty of inhibiting inﬂammatory mediators production, such as IL-6,
interferon-g, TNF-a, and MCP-1 in vitro and in vivo, and could be a
validity anti-inﬂammatory agent [19e21]. In our previous study, we
have reﬁned the formula Qingyi Decoction based on Chinese
medicine theory and devised a Chinese patent medicine “Emodin&
Baicalei”. The combined use of Baicalein and Emodin showed a
therapeutic effect on pancreatic injuries in SAP rats [17,18]. How-
ever, the effectiveness of use of Baicalein alone on SAP and whether
it is reasonable to combine Baicalein and Emodin has not been
reported. Therefore, we have designed animal experiments to study
the therapeutic effects of independent use of Baicalein on SAP and
inﬂammatory cytokine production in rats, thus providing oppor-
tunities for the progression of better treatment approaches in SAP.
2. Materials and Methods
2.1. Materials
84 male Sprague-Dawley (SD) rats weighing 300e310 g were
used in this study. The animals were purchased from the Experi-
mental Animal Center of Xi'an Jiaotong University Health Science
Center (Xi'an, China), fed standard laboratory and fasted overnight
preoperatively, with free access to water. All procedures in rats
were approved by the Institutional Animal Use and Care Committee
of Xi'an Jiaotong University Health Science Center and performed
according to the National Guide for the Care and Use of Laboratory
Animals. Sodium taurocholate, Baicalein, and sodium pentobarbital
were purchased from SigmaeAldrich (St. Louis, MO, USA). IL-6 and
TNF-a enzyme-linked immunosorbent assay (ELISA) kits were ob-
tained from Senxiong Biotech (Shanghai, China). The Amylase Kit
was purchased from Jiancheng Biotech (Nanjing, China).
2.2. SAP model preparation
After fasting overnight, 84 rats were divided into sham opera-
tion (SO), SAP model (SAP), and Baicalein treatment (BA) groups
randomly (n ¼ 28). Each group was randomly allocated to three
subgroups for the time points of 3, 6, and 12 h after the operation (8
rats in 3 h and 6 h time point groups, 12 rats in the 12 h time point
group). SAP was induced in rats of the SAP and BA groups using the
modiﬁed protocol of Schmidt J et al. [22]. Surgical anesthesia was
induced with an intraperitoneal injection of sodium pentobarbital(50 mg/kg, SigmaeAldrich) and the abdomen was opened by a
midline incision. The duodenum and the common bile duct were
identiﬁed. The common biliopancreatic duct was advanced with a
catheter and the hepatic duct was closed with a small bulldog
clamp to prevent backﬂow. SAP model was induced by retrograde
injection into the common biliopancreatic duct of 5% sodium
taurocholate (SigmaeAldrich) at a dose of 0.1 mL/100 g body
weight (with 0.1 mL/min injection velocity). Then, the injecting
point was pressed for 3 min and the surgery ﬁnished with
abdominal stratiﬁed closing. Special attention was focused on
atraumatic surgical technique. In the SO group, incisions were
closed immediately following the turning over of the pancreas.
Baicalein (20 mg/kg) was injected via tail vein to fasted rats of the
BA group. SO and SAP rats were given a same amount of normal
saline. Animals were anesthetized with sodium pentobarbital 3, 6,
or 12 h after the surgery and a laparotomy performed. Intracardiac
bloodwas collected from the right ventricle, centrifuged at 1800 g
for 10 min and the serum stored at 20 C for subsequent analysis.
Ascites ﬂuid was harvested and weight. The entire pancreas was
removed immediately and immersion ﬁxed in 4% para-
formaldehyde in anatomic orientation, then embedded in parafﬁn,
and sectioned at 4 mm for histologic analysis.2.3. Detection of 12-h mortality and ascites ﬂuid amount in SAP
rats
The mortality of rats was determined by calculating the
numbers of surviving and dead rats in every group over the 12 h
post-surgery. The ascites ﬂuid amount was assayed by the differ-
ence of gauze weight before and after being placed in the abdom-
inal cavity to last for 5 min.2.4. Histopathologic analysis
The removed entire pancreatic tissues were immersion ﬁxed in
4% paraformaldehyde for 24 h, followed by dehydrating and
embedding in parafﬁn using a routine protocol. The parafﬁn-
embedded tissue samples were cut at 4 mm thick at longitudinal
section and stained with hematoxylin and eosin. The slides were
scored by two blinded experienced pathologists, and the histo-
pathological changes of the pancreatic tissue were evaluated by
light microscopy. Two slides and ten ﬁelds/slide were examined for
histopathological analysis in each pancreas. The histopathology
scoring criteria were: edema, acinar necrosis, hemorrhages, and
inﬂammation. We complied the standardized scoring system
J. Li et al. / Biochemical and Biophysical Research Communications 466 (2015) 664e669666deﬁned with Spomam et al. [23] as shown in Table 1, and the ﬁnal
score of each section was the summation of each pathological
parameter.
2.5. Measurement of amylase activity and pro-inﬂammatory
cytokine level in serum
The serum amylase activity was determined according to the
instruction of manufacturer (Jiancheng Biotech, Nanjing, China).
Serum IL-6 and TNF-a concentrations were measured by
commercially available ELISA kits (Senxiong Biotech, Shanghai,
China) complying with the manufacturer's protocols. Absorbance
was detected at 450 nm by a microplate mode reader (BioTek Inc.,
Winooski, VT, USA).
2.6. Statistical analysis
All datawere presented as themeans± standard deviation (S.D).
Statistical comparisons were made by analysis of variance (SPSS
ver. 14.0; SPSS Software, Chicago, USA). A probability of experi-
mental error <5% (P < 0.05) was considered acceptable for statis-
tical signiﬁcant difference.
3. Results
3.1. Baicalein reduces the 12-h mortality and ascites ﬂuid amount
in SAP rats
The mortality 12 h after SAP induction in SAP group was 50%,
and Baicalein markedly decreased this mortality (Fig. 1a, P < 0.01).
The amount of ascites ﬂuid in SAP group also increased signiﬁcantly
at 3, 6, and 12 h time points compared with the SO group (Fig. 1b,
P< 0.01). Treatmentwith Baicalein greatly decreased the amount of
ascites ﬂuid at the 12 h time point (Fig. 1b, P < 0.05). However,
Baicalein did not affect the ascites ﬂuid at 3, 6 h (Fig. 1b, P > 0.05).
3.2. Baicalein attenuates the severity of pancreatic injury
SO group showed entirely normal acinar architecture. SAP group
demonstrated pancreatic injury characterize by moderate tissue
edema, light hemorrhage and necrosis at 3 h time point after SAP
induction compared with SO group. As time progressed, the
severity of pancreatic injury deteriorated and there were grosslyFig. 1. (a) Effect of Baicalein on the 12 h mortality of SAP rats. Animals were administrate
evaluated by calculating the numbers of surviving and dead rats over the 12 h post-surgery.
at 3, 6, and 12 h time points of SAP rats. Animals were administrated with Baicalein or norma
weight before and after being placed in the abdominal cavity to last for 5 min. Data represent
group).edema and sublobular hemorrhages associated with obvious
neutrophil inﬁltration and parenchymal necrosis by 6 h after SAP
induction. 12 h after SAP induction, the pancreas showed massive
fat and parenchymal necrosis, inﬂammatory inﬁltration, cell lysis,
and a reduction in cell number plus the aforementioned damage
(Fig. 2aec). Treatment with Baicalein ameliorated pancreatic injury
and decreased the histopathology scores at the 6 h and 12 h time
points (Fig. 2, P < 0.05), but exhibited no inﬂuence at 3 h (Fig. 2,
P > 0.05).
3.3. Effect of Baicalein on serum amylase activity in SAP rats
The serum amylase activity in SAP group increased signiﬁcantly
at 3, 6, and 12 h time points compared with SO group (Fig. 3,
P < 0.01). However, treatment with Baicalein did not affect the
serum amylase activity (Fig. 3, P > 0.05).
3.4. Baicalein reduces the serum level of pro-inﬂammatory
cytokines
Compared with the SO group, serum level of IL-6 and TNF-a in
SAP group were increased signiﬁcantly at 3, 6, and 12 h time points
(Fig. 4, P < 0.01). Baicalein treatment markedly decreased the level
of the pro-inﬂammatory cytokines at the 6 h and 12 h time points
(Fig. 4, P < 0.05), but showed no action at 3 h (Fig. 4, P > 0.05).
4. Discussion
To date, there is no speciﬁc treatment for SAP. However, this
study highlighted the therapeutic effect of Baicalein against SAP in
a rat model. In our study of pancreatitis induced by taurocholate,
both rat mortality and pancreatic tissue pathology score were
reduced after Baicalein treatment, thus demonstrating the thera-
peutic beneﬁts of Baicalein in SAP. The pathological changes pre-
sent in the pancreas during SAP pathogenesis are complicated. This
process is associated with pancreas autodigestion by prematurely
activated digestive enzymes, acinar rupture, vasodilatation,
increased blood ﬂow, and inﬂammatory cell inﬁltration, which
could all lead to pancreatic injury [4]. The results demonstrated
that compared with SO group, the histopathology scores were
signiﬁcantly elevated at 3, 6 and 12 h time points in SAP rats.
Pancreatitis-speciﬁc changes were showed as tissue edema,
neutrophil inﬁltration, parenchymal hemorrhage, and acinar celld with Baicalein or normal saline immediately after SAP induction. The mortality was
Data represents mean ± S.D (*P < 0.01). (b) Baicalein decreased the ascites ﬂuid amount
l saline after SAP induction. Ascites ﬂuid amount was assayed by the difference of gauze
s mean ± S.D (*P < 0.01 compared with the SO group. **P < 0.05 compared with the SAP
Fig. 2. Effect of Baicalein on histological changes and histopathology scores for pancreatic tissues at 3, 6, and 12 h time points. Animals were administrated with Baicalein or normal
saline after SAP induction. Histopathology scores were evaluated complied the standardized scoring system described in Materials and Methods. (a) SO group; (b) SAP group; (c) BA
group. The SAP group exhibited massive parenchymal and fat necrosis, extensive hemorrhaging and cell number decrease, while in the SO group the change was not remarkable.
The BA group exhibited few pathological changes, pancreatic tissue showed little edema and no inﬂammatory inﬁltrate 12 h after SAP induction; (d) The histopathology scores
increased at all tine points after SAP induction. Treatment with Baicalein markedly reduced the histopathology scores at 6-h and 12-h time points. Data represents mean ± S.D
(*P < 0.01 compared with the SO group. **P < 0.05 compared with the SAP group).
Fig. 3. Effect of Baicalein on serum amylase activity at 3, 6, and 12 h time points.
Serum amylase activity was determined as described in Materials and Methods. Serum
amylase activity increased signiﬁcantly after SAP induction at all time points. However,
treatment with Baicalein did not alter the serum amylase activity. Data represents
mean ± S.D (*P < 0.01 compared with the SO group).
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tration reduced the pathologic scores at all time points, indicating
the amelioration of pancreatic injury. Improving survival rate has
become a standard criterion to estimate the efﬁcacy of a drug, so
the therapeutic effect of Baicalein on SAP is worth further study.
The pathogenesis of SAP is poorly understood. At present, it is
known that the “inﬂammatory reaction” hypothesis plays a critical
role in the pathophysiology of SAP and current research continues
to focus on its mechanism. The excessive inﬂammatory reaction(SIRS) is suggested to be the main cause of high mortality and
morbidity in SAP [3]. TNF-a and IL-6 are known to participate in the
initiation and progression of SAP. TNF-a is thought to initiate a
cascade of inﬂammatory reactions and be a reliable predictor of
outcome in SAP [24,25]. IL-6 is also a principal pro-inﬂammatory
cytokine and has been identiﬁed as the most reliable prognostic
factor in SAP [26]. Previous studies have shown that up-regulation
of both IL-6 and TNF-a in pancreas and serumwere observed in SAP
induced by taurocholate [24,27]. In our study, we similarly found
that serum IL-6 and TNF-a were considerably higher than in SO
group at all time points and that Baicalein reduced serum IL-6 and
TNF-a at 6 and 12 h time points after SAP induction. We ﬁrst time
provided important data showing that Baicalein can attenuate the
pro-inﬂammatory cytokines production in SAP, thus effectively
protecting pancreatic tissue injury.
There is evidence to show that Baicalein display many biological
effects, including antipyretic, antibacterial, and anti-inﬂammatory
properties. Previous studies revealed Baicalein could suppress the
multiple inﬂammatorymediators generation, including IL-6, TNF-a,
INF-g, and MCP-1 both in vitro and in vivo and could be a potential
anti-inﬂammatory agent [19e21]. However, independent use of
Baicalein on SAP has not been reported and the effect of Baicalein is
still not fully clariﬁed. In our study, we ﬁrst time found Baicalein
exhibited inhibitory effects on pro-inﬂammatory cytokine pro-
duction, decreasing the serum IL-6 and TNF-a concentrations and
attenuating the inﬂammatory response in SAP.
In addition to increased migration of inﬂammatory cells and
pro-inﬂammatory cytokine release, SAP causes damage to vascular
endothelial cells and increased plasma extravasation, leading to the
accumulation of ascites ﬂuid [22]. In our study, SAP induced in rats
Fig. 4. ELISA showing that Baicalein affects serum level of pro-inﬂammatory cytokines
at 3, 6, and 12 h time points. The level of serum IL-6 and TNF-a increased signiﬁcantly
in the SAP group at all time points investigated. Baicalein administration markedly
reduced the level of pro-inﬂammatory cytokines at 6 and 12 h time points. Data
represents mean ± S.D (*P < 0.01 compared with the SO group. **P < 0.05 compared
with the SAP group).
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ascites and increased ascites ﬂuid amount compared with the SO
group. Baicalein reduced the ascites ﬂuid volume 12 h after SAP
induction, demonstrating the anti-inﬂammatory activity of Baica-
lein can reduce capillary permeability and protect the capillary
walls.
The amylase test is a standardization in the clinical diagnosis of
SAP. Determination of serum amylase activity reveals inﬂammation
in the pancreas. In this study, we found serum amylase activity was
elevated in SAP rats at 3 h, 6 h, and 12 h after SAP model induction.
However, the degree of increased amylase does not necessarily
equal the severity of SAP. Some patients with mild pancreatitis may
have high amylase activity, while some have moderate amylase
activity but acute necrotizing pancreatitis. Thus, the level of
amylase activity cannot serve as a diagnostic standard to estimate
the prognosis of SAP. This may explain why Baicalein attenuates
SAP, but does not decrease the amylase activity.
Results in our study indicated that inﬂammation should be a
major target for developing therapy for SAP and remains our
greatest challenge in the ﬁeld of SAP research. Baicalein demon-
strated good therapeutic effects in SAP and has great future po-
tential. Although details of the molecular mechanisms of the anti-
inﬂammatory properties of Baicalain in SAP remain unclear, it
demonstrate a good perspective for SAP therapy and deserve to
lucubrate.
Baicalein both signiﬁcantly suppressed the inﬂammatory
response and reduced pancreatic injury in SAP. It also improvedsurvival in SAP rats. Thus, Baicaleinmay be a candidate drug for SAP
therapy with good perspective. However, the insufﬁciency of our
research was that there is a deﬁciency on speciﬁc mechanisms
study of Baicalein. Further experiments are therefore necessary to
illustrate the pharmacologic mechanisms of Baicalein on SAP. As
lacking any speciﬁc therapy for SAP has been a serious shortcoming
of current treatments, Baicalein may provide beneﬁts for SAP pa-
tients in the future.
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